We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Indivior Plc | LSE:INDV | London | Ordinary Share | GB00BN4HT335 | ORD USD0.50 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-22.00 | -1.50% | 1,441.00 | 1,440.00 | 1,443.00 | 1,461.00 | 1,425.00 | 1,450.00 | 112,102 | 13:10:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.09B | 2M | 0.0148 | 974.32 | 1.95B |
Date | Subject | Author | Discuss |
---|---|---|---|
06/4/2019 09:34 | NOT TOTALLY IGNORED ENJOY YOUR WEEKEND AND LETS EXPECT AN EXCITING UPWARD NEXT WEEK | grupo guitarlumber | |
06/4/2019 09:30 | (INDV) Delayed London Stock Exchange - 04/05 04:35:20 pm 99.16 GBp +1.29% | grupo guitarlumber | |
06/4/2019 09:11 | excellent news yesterday on the efficacy of Sublocade went unnoticed by the market. That us the company being valued at less than net cash in a strong market leaves me scratching my head | dealy | |
28/3/2019 20:50 | I agree. The dust will settle though and these will recover again. | rafieh | |
28/3/2019 17:50 | The overhang in this sub sector is as a result of the New York State's legal action against a number of companies, including J and J and Teva , addressing the opiod market. All in this area have had their share prices hit. | gregmorg | |
28/3/2019 12:59 | Keep it hush otherwise they make sure it goes back down lol | pally12 | |
28/3/2019 08:45 | Buyers are coming back. Repeat journey to 110+ has started. | rafieh | |
27/3/2019 13:24 | a lot of my small caps have fallen 20% on no news over the last few days | dealy | |
27/3/2019 13:07 | Should bounce from these levels, or thereabouts. | rafieh | |
27/3/2019 12:43 | 92.93 GBp -9.60% | grupo guitarlumber | |
27/3/2019 12:41 | 03/27/19 Academy of Managed Care Pharmacy Meeting | grupo guitarlumber | |
27/3/2019 12:24 | Nasty fall on no news unless a leak on Q1 revenues. | sparky333 | |
27/3/2019 12:03 | Looks ripe for a bid especially with the cash. | sparky333 | |
27/3/2019 11:33 | Looking interesting at this level | sparky333 | |
27/3/2019 11:33 | What's happening here? This usually bounces before now. | upsondowns | |
26/3/2019 15:08 | Have you taken into account the 438M USD provision which the Annual Report says may not be enough? | ewanwhose | |
26/3/2019 10:21 | Time to sell lol | pally12 | |
26/3/2019 09:23 | Something fishy and or Friday 29 March 2019 4 witches approaches cheers | grupo guitarlumber | |
26/3/2019 08:56 | 03/27/19 Academy of Managed Care Pharmacy Meeting | grupo guitarlumber | |
26/3/2019 08:49 | This is old news. Should not affect the price today. The drop today is part of the usual fluctuations we have seen over the last 3-4 months. | rafieh | |
26/3/2019 08:31 | Dr. Reddy’s Wants Indivior to Pay $70 Million for Opioid Delay By Ari Altstedter 11 mars 2019 à 10:59 UTC+1 Updated on 11 mars 2019 à 22:30 UTC+1 Indivior blocked Dr Reddy’s generic version of Suboxone Film U.S. Supreme Court had lifted the injunction last month Dr. Reddy’s Laboratories Ltd. is seeking more than $70 million from Indivior Plc as compensation for lost U.S. sales of its generic version of a leading opioid addiction treatment that was delayed in a patent dispute with the U.K.-based drugmaker. Indivior had managed to block Dr. Reddy’s generic version of Suboxone Film through a court injunction in July, despite the Indian company receiving regulatory approval earlier to sell the market-leading product for treating opioid dependence. Last month, the U.S. Supreme Court refused to uphold that injunction, allowing Dr. Reddy’s to resume sales of the drug. | grupo guitarlumber | |
26/3/2019 08:24 | company is currently valued at net cash. no value assigned to the products or IP. insanely low valuation | dealy | |
26/3/2019 08:17 | Time to top up, or open a short term trade. | rafieh |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions